Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japan Approves Biosimilar Teriparatide And Darbepoetin

Executive Summary

Japan’s first biosimilar teriparatide has been approved for Mochida Pharmaceutical, while competition in the darbepoetin alfa arena looks set to step up following two recent authorizations.

You may also be interested in...



Dong-A Makes Deal For Darbepoetin Alfa With Turkey’s Polifarma

Korean developer Dong-A has signed an exclusive licensing deal with Turkey’s Polifarma covering its darbepoetin biosimilar version of Aranesp/Nesp in Turkey, Brazil and Mexico.

Chong Kun Dang Signs Nesp Biosimilar Deal In Persian Gulf

Chong Kun Dang’s Nesbell (darbepoetin alfa) biosimilar is set to head to the Persian Gulf under a technology transfer and commercialization agreement with Oman-based Menagen Pharmaceutical Industries.

Mochida Debuts Japanese Teriparatide Biosimilar

Mochida has launched the first Japanese teriparatide biosimilar rival to Eli Lilly’s blockbuster osteoporosis drug Forteo. The company is hoping for big sales for the injectable in the country where the government is aiming to rein in healthcare costs for its rapidly ageing population.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB149200

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel